Table of Content


Chapter 1   Methodology and Scope
1.1    Market scope and definition
1.2    Research design
1.2.1    Research approach
1.2.2    Data collection methods
1.3    Base estimates and calculations
1.3.1    Base year calculation
1.3.2    Key trends for market estimation
1.4    Forecast model
1.5    Primary research and validation
1.5.1    Primary sources
1.5.2    Data mining sources
Chapter 2   Executive Summary
2.1    Industry 360? synopsis
Chapter 3   Industry Insights
3.1    Industry ecosystem analysis
3.2    Industry impact forces
3.2.1    Growth drivers
3.2.1.1   Rising prevalence of cardiovascular diseases
3.2.1.2   Advancements in drug development
3.2.1.3   Increasing lifestyle-related risk factors
3.2.2    Industry pitfalls and challenges
3.2.2.1   Side effects associated with the drugs
3.2.2.2   Growing adoption of minimally invasive surgeries
3.3    Growth potential analysis
3.4    Regulatory landscape
3.5    Pipeline analysis
3.6    Porter’s analysis
3.7    PESTEL analysis
Chapter 4   Competitive Landscape, 2024
4.1    Introduction
4.2    Company matrix analysis
4.3    Competitive analysis of major market players
4.4    Competitive positioning matrix
4.5    Strategy dashboard
Chapter 5   Market Estimates and Forecast, By Type, 2021 – 2034 ($ Mn)
5.1    Key trends
5.2    Stable angina
5.3    Unstable angina
5.4    Microvascular angina
5.5    Prinzmetal angina
Chapter 6   Market Estimates and Forecast, By Drug Class, 2021 – 2034 ($ Mn)
6.1    Key trends
6.2    Beta blockers
6.3    Nitrates
6.4    Anti-platelets
6.5    Calcium channel blockers
6.6    Anticoagulants
6.7    ACE inhibitors
6.8    Other drug classes
Chapter 7   Market Estimates and Forecast, By Route of Administration, 2021 – 2034 ($ Mn)
7.1    Key trends
7.2    Oral
7.3    Injectable
7.4    Topical
Chapter 8   Market Estimates and Forecast, By Distribution Channel, 2021 – 2034 ($ Mn)
8.1    Key trends
8.2    Hospital pharmacies
8.3    Retail pharmacies
8.4    Online pharmacies
Chapter 9   Market Estimates and Forecast, By Region, 2021 – 2034 ($ Mn)
9.1    Key trends
9.2    North America
9.2.1    U.S.
9.2.2    Canada
9.3    Europe
9.3.1    Germany
9.3.2    UK
9.3.3    France
9.3.4    Italy
9.3.5    Spain
9.3.6    Netherlands
9.4    Asia Pacific
9.4.1    China
9.4.2    Japan
9.4.3    India
9.4.4    Australia
9.4.5    South Korea
9.5    Latin America
9.5.1    Brazil
9.5.2    Mexico
9.5.3    Argentina
9.6    Middle East and Africa
9.6.1    South Africa
9.6.2    Saudi Arabia
9.6.3    UAE
Chapter 10   Company Profiles
10.1    AdvaCare Pharma
10.2    Amgen
10.3    AstraZeneca
10.4    Bayer
10.5    Boehringer Ingelheim International
10.6    Eli Lilly and Company
10.7    Gilead Sciences
10.8    GlaxoSmithKline
10.9    Merck
10.10   Novartis
10.11   Otsuka Pharmaceutical
10.12   Pfizer
10.13   Sanofi